Apimeds Pharmaceuticals Files 8-K for Bylaws and Financials
Ticker: APUS · Form: 8-K · Filed: Oct 16, 2025 · CIK: 1894525
| Field | Detail |
|---|---|
| Company | Apimeds Pharmaceuticals Us, INC. (APUS) |
| Form Type | 8-K |
| Filed Date | Oct 16, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting, bylaws
TL;DR
APIM filed an 8-K for bylaw changes & financials as of Oct 15, 2025.
AI Summary
Apimeds Pharmaceuticals US, Inc. filed an 8-K on October 16, 2025, reporting amendments to its Articles of Incorporation or Bylaws and financial statements. The company, incorporated in Delaware with its principal executive offices in Matawan, New Jersey, operates in the Pharmaceutical Preparations industry. The filing date indicates a report as of October 15, 2025.
Why It Matters
This filing provides updates on Apimeds Pharmaceuticals' corporate governance and financial reporting, which are crucial for investors to assess the company's operational status and compliance.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not indicate any immediate financial distress or significant operational changes.
Key Numbers
- 001-42545 — SEC File Number (Identifies the company's filing with the SEC.)
- 85-1099700 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- Apimeds Pharmaceuticals US, Inc. (company) — Registrant
- October 15, 2025 (date) — Date of earliest event reported
- October 16, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Matawan, New Jersey (location) — Principal executive offices
- 2834 (sic_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What specific amendments were made to Apimeds Pharmaceuticals' Articles of Incorporation or Bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the provided text excerpt.
What is the primary business of Apimeds Pharmaceuticals US, Inc.?
Apimeds Pharmaceuticals US, Inc. operates in the Pharmaceutical Preparations industry, with a Standard Industrial Classification code of 2834.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on October 15, 2025.
Where are Apimeds Pharmaceuticals US, Inc.'s principal executive offices located?
The principal executive offices of Apimeds Pharmaceuticals US, Inc. are located at 100 Matawan Rd, Suite 325, Matawan, New Jersey, 07747.
What is the SEC file number for Apimeds Pharmaceuticals US, Inc.?
The SEC file number for Apimeds Pharmaceuticals US, Inc. is 001-42545.
Filing Stats: 473 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-10-16 16:15:27
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share APUS NYSE American LLC
Filing Documents
- ea0261543-8k_apimeds.htm (8-K) — 23KB
- ea026154301ex3-1_apimeds.htm (EX-3.1) — 2KB
- 0001213900-25-099553.txt ( ) — 191KB
- apus-20251015.xsd (EX-101.SCH) — 3KB
- apus-20251015_lab.xml (EX-101.LAB) — 33KB
- apus-20251015_pre.xml (EX-101.PRE) — 22KB
- ea0261543-8k_apimeds_htm.xml (XML) — 4KB
03. Amendments to Articles of Incorporation or Bylaws; Change
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On October 15, 2025, the board of directors of Apimeds Pharmaceuticals US, Inc. (the "Company") amended the bylaws to allow shareholder action by written consent. The foregoing description of the Amendments does not purport to be complete and is qualified in its entirety by reference to the full text of the form of the Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 First Amendment to Bylaws dated October 15, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Apimeds Pharmaceuticals US, Inc. Date: October 16, 2025 By: /s/ Erik Emerson Name: Erik Emerson Title: Chief Executive Officer 2